Gregg Alton serves as the CEO of Gilead Sciences, Inc. He took on the role temporarily in 2019 after being the Chief Patient Officer. Gregg has been with Gilead for over 20 years, leading important decisions and strategies to enhance...
Gregg Alton serves as the CEO of Gilead Sciences, Inc. He took on the role temporarily in 2019 after being the Chief Patient Officer. Gregg has been with Gilead for over 20 years, leading important decisions and strategies to enhance patient access to medicines worldwide. A Stanford Law School graduate, he has a strong legal background and has held key positions in medical affairs and corporate strategy at Gilead. In recent years, his stock holdings have fluctuated significantly, peaking at over $6 million, showcasing his personal investment in the company's performance. Interestingly, he did not receive a traditional salary in 2019, which reflects Gilead's focus on aligning compensation with company success. Instead, he earned bonuses tied to the company's performance metrics, truly committing to Gilead's vision of making life-saving treatments accessible to all.